Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma.
Kazuki MaesakaRyotaro SakamoriRyoko YamadaAkira DoiYuki TahataMasanori MiyazakiKazuyoshi OhkawaEiji MitaSadaharu IioYasutoshi NozakiTakayuki YakushijinYasuharu ImaiTakahiro KodamaHayato HikitaTomohide TatsumiTetsuo TakeharaPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2022)
Atezolizumab plus bevacizumab showed prolonged PFS, maintained hepatic reserve, and had lower rates of severe AEs compared with that on using lenvatinib as primary systemic chemotherapy for HCC.